Results 11 to 20 of about 1,341 (168)

The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials

International Journal of Clinical Practice, 2023
In this study, we conducted a meta-analysis to assess the efficacy and safety of teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed, and Embase databases from inception to May 25, 2022, and included all randomized ...
Fei Lin, Qiu’e Yao, Bin Yu, Zehui Deng, Jingyue Qiu, Rong He   +5 more
doaj   +3 more sources

Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms [PDF]

Case Reports in Endocrinology
Graves’ disease is an autoimmune thyroidopathy associated with hyperthyroidism and nonendocrine manifestations such as thyroid eye disease (TED), pretibial myxedema, and thyroid acropachy.
Soumya Chatterjee
doaj   +3 more sources

Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report [PDF]

Case Reports in Ophthalmology, 2023
Teprotumumab is a novel insulin-like growth factor-1 receptor inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation. To date, an effective protocol for managing hearing loss in this
Tracy J. Lu, Linus Amarikwa, Bryan J. Winn, Michelle Inserra, Chrysoula Dosiou, Andrea L. Kossler   +5 more
doaj   +2 more sources

Teprotumumab in advanced reactivated thyroid eye disease

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report the case of a patient with reactivated, refractory thyroid eye disease (TED) treated with teprotumumab. Observations: A 51-year-old female with a 16-year history of thyroid eye disease previously treated with orbital decompression and ...
Olivia T. Cheng, Dianne M. Schlachter
doaj   +2 more sources

Teprotumumab for Thyroid-Associated Ophthalmopathy [PDF]

New England Journal of Medicine, 2017
Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the ...
Smith, Terry J, Kahaly, George J, Ezra, Daniel G, Fleming, James C, Dailey, Roger A, Tang, Rosa A, Harris, Gerald J, ANTONELLI, ALESSANDRO, Salvi, Mario, Goldberg, Robert A, Gigantelli, James W, Couch, Steven M, Shriver, Erin M, Hayek, Brent R, Hink, Eric M, Woodward, Richard M, Gabriel, Kathleen, Magni, Guido, Douglas, Raymond S.   +18 more
core   +9 more sources

Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study [PDF]

Endocrine Connections
Teprotumumab, a monoclonal antibody that antagonizes the insulin-like growth factor 1 receptor, is the first medication within the United States to receive Food and Drug Administration (FDA) approval for thyroid eye disease (TED). The FDA recently issued
Maxim John Levy Barnett, Justin Lam, Mikaela Nikkola Jara-Tantoco, Carlo Casipit, Sarah Eidbo, Catherine Anastasopoulou   +5 more
doaj   +2 more sources

Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety [PDF]

Frontiers in Endocrinology
BackgroundThyroid eye disease (TED) is a sight-threatening autoimmune disorder with limited effective therapies. Teprotumumab, an insulin-like growth factor-1 receptor inhibitor, has emerged as a promising treatment. However, a comprehensive synthesis of
Rongjing Song, Wei Zhao, Shasha Li, Xiaofang Niu, Jing Guo, Xiuying Zhang, Xiaohong Zhang, Xiaohong Zhang, Linong Ji   +8 more
doaj   +2 more sources

Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy [PDF]

European Thyroid Journal
Background: In 2021, the European Group on Graves’ orbitopathy (EUGOGO) published clinical practice guidelines for the management of GO, and in 2022, the American and European Thyroid Associations published the ATA/ETA consensus statement on the same ...
Luigi Bartalena, Daniela Gallo, George J Kahaly, Michele Marinò, Maria Laura Tanda   +4 more
doaj   +2 more sources

Teprotumumab [PDF]

Reactions Weekly, 2021
Teprotumumab, a monoclonal antibody targeted against the insulin-like growth factor 1 (IGF-1) receptor, was recently approved by the United States Food and Drug Administration for the treatment of thyroid eye disease (TED).
Bryan J. Winn, Robert C. Kersten
core   +4 more sources

Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review [PDF]

Frontiers in Endocrinology
Teprotumumab has shown significant efficacy in treating Thyroid Eye Disease (TED), but its adverse effects require careful management. Key reactions include hearing impairment, hyperglycemia, and potential exacerbation of pre-existing inflammatory bowel ...
Zhibin Xu, Nan Hu, Qitao Chen, Yue Zhou, Yunye Huang, Songhao Hu, Haoru Jin, Yubo Tang   +7 more
doaj   +2 more sources